Home » Stocks » CSTL

Castle Biosciences, Inc. (CSTL)

Stock Price: $79.17 USD -1.51 (-1.87%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $78.90 -0.27 (-0.34%) Jan 22, 7:42 PM
Market Cap 1.96B
Revenue (ttm) 62.98M
Net Income (ttm) -3.34M
Shares Out 19.94M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $79.17
Previous Close $80.68
Change ($) -1.51
Change (%) -1.87%
Day's Open 79.63
Day's Range 76.51 - 80.99
Day's Volume 176,757
52-Week Range 23.08 - 81.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 4 days ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Derma...

Business Wire - 1 week ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Castle--Castle today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.

Business Wire - 2 weeks ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021.

Business Wire - 1 month ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #skincancer--Castle today announced it prepaid in full its outstanding term loan facility.

Business Wire - 1 month ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences today announced the closing of its previously announced underwritten public offering.

Business Wire - 1 month ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences announced today the pricing of its underwritten public offering.

Business Wire - 1 month ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle announced today that it has commenced a proposed underwritten public offering.

Business Wire - 1 month ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma

Business Wire - 2 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #cancerdiagnostics--Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

Business Wire - 2 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicio...

Business Wire - 2 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDP2020--Castle today announced the presentation of data on two of its skin cancer gene expression profile tests during the 57th Meeting of ASDP.

Zacks Investment Research - 2 months ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Catalyst Biosciences (CBIO), UFP Industries (UFPI), VeriSign (VRSN), InMode (INMD) and...

Other stocks mentioned: CBIO, INMD, UFPI, VRSN
Seeking Alpha - 2 months ago

Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #earnings--Castle today announced its financial results for the third quarter and nine months ended Sept. 30, 2020.

Business Wire - 2 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle's president and CEO will present a company overview at the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum on Nov. 19, 2020

Business Wire - 2 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #GeneExpressionProfile--Castle Biosciences announced that DecisionDx® DiffDx™-Melanoma is now commercially available.

Business Wire - 2 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDP--Castle will deliver two poster presentations at The ASDP 57th Virtual Annual Meeting.

Business Wire - 2 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the third quarter ended Sept. 30, 2020, after the close of market on Monday, Nov...

Business Wire - 3 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle today announced that it will host an investor webcast to highlight the planned launch of the ConfirmDx®-Melanoma test.

Zacks Investment Research - 3 months ago

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: DQ, HRI, SURF
Business Wire - 3 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences Presents Data on DecisionDx-Melanoma at the Virtual European Association of Dermato-Oncology (EADO) Congress.

Business Wire - 3 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle announced its data were featured in two oral presentations during the 2020 ASDS Virtual Annual Meeting, Oct. 9-11, 2020.

Business Wire - 3 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced that Palmetto GBA MolDx has issued a final expanded local coverage determination for the company's DecisionDx...

Business Wire - 3 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle announced its data will be featured in oral presentations during the 2020 American Society for Dermatologic Surgery Virtual Annual M...

Seeking Alpha - 5 months ago

Castle Biosciences, Inc.'s (CSTL) CEO Derek Maetzold on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 80.95% and 39.02%, respectively, for the quarter ended June 2020.

Zacks Investment Research - 5 months ago

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Business Wire - 6 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions...

Business Wire - 6 months ago

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions...

Seeking Alpha - 8 months ago

Castle Bisociences Grows Despite Covid19 Damping

Seeking Alpha - 8 months ago

Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Castle Biosciences.

Zacks Investment Research - 9 months ago

Castle Biosciences (CSTL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 9 months ago

Castle Biosciences, Inc. (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 9 months ago

Castle Biosciences, Inc. (CSTL) has been struggling lately, but the selling pressure may be coming to an end soon.

Seeking Alpha - 10 months ago

Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q4 2019 - Earnings Call Transcript

About CSTL

Castle Biosciences, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary product... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jul 25, 2019
CEO
Derek J. Maetzold
Employees
133
Stock Exchange
NASDAQ
Ticker Symbol
CSTL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is 72.80, which is a decrease of -8.05% from the latest price.

Price Target
$72.80
(-8.05% downside)
Analyst Consensus: Strong Buy